Items Tagged ‘erbitux’

October 16th, 2017

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer


Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in […]

View full entry

Tags: BRAF, Colon Cancer, erbitux, News, Precision Cancer Medicine, Rectal Cancer, V600E, vemurafenib, zelboraf

August 5th, 2014

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors


Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had stopped responding to the EGFR inhibitors Tarceva® (erlotinib) and Iressa® (gefitinib). This novel combination appeared to benefit patients regardless of whether their […]

View full entry

Tags: EGFR, erbitux, gilotrif, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell

June 20th, 2014

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer


In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or FOLFIRI) regimens led to a new benchmark median survival time of 29 months. The results presented as ASCO were from the […]

View full entry

Tags: asco, avastin, Colon Cancer, colorectal cancer, erbitux, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer